Search results for "Juva"

showing 10 items of 739 documents

Depressed Prostaglandin Release from Peritoneal Cells Induced by a T Cell Adjuvant, Lentinan

1979

Abstract PGE and PGF release from peritoneal exudate cells was studied in mice after injection with two s (1–3) glucans, the antitumor active lentinan and the inactive pachyman. 4 days after injection of both polysaccharides, the spontaneous and phagocytosis-induced PGE and PGF release was markedly suppressed. However, only the immunopotentiator lentinan induced peritoneal exudate cells which exhibited a longer lasting diminished PG release. The data suggest that the T cell adjuvant lentinan may potentiate cellular immune responses by reducing synthesis of immune suppressive prostaglandins from peritoneal exudate cells.

chemistry.chemical_classificationmedicine.medical_specialtymedicine.medical_treatmentT cellLentinanProstaglandinGeneral MedicineImmunopotentiatorPharmacologyPolysaccharidechemistry.chemical_compoundmedicine.anatomical_structureImmune systemEndocrinologychemistryInternal medicinePeritoneal exudatemedicinelipids (amino acids peptides and proteins)AdjuvantZeitschrift für Immunitätsforschung: Immunobiology
researchProduct

Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics

2011

Nicola Scichilone, Chiara Minaldi, Roberta Santagata, Salvatore Battaglia, Gaetana Camarda, Vincenzo Bellia Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S.), Sezione di Pneumologia, University of Palermo, Palermo, ItalyBackground: The ultra-short course pre-seasonal allergy vaccine, containing appropriate allergoids with the adjuvant monophosphoryl lipid A (MPL), may be effective in treating allergic symptoms. Objective: To explore the timing of the immunological responses to the pre-seasonal allergy vaccine.Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered to 20 Parietaria-sensitive intermittent asthmatics (M/F: 12/8; …

exhaled breath condensatelcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeAnti-inflammatoryAllergenJournal of Asthma and AllergymedicineImmunology and AllergyExhaled breath condensateOriginal ResearchAsthmabiologybusiness.industryasthmabiology.organism_classificationmedicine.diseaseinflammationpollenallergen asthma immunotherapy inflammation pollen exhaled breath condensateImmunologyParietaria judaicaimmunotherapylcsh:RC581-607businessAdjuvantallergenJournal of Asthma and Allergy
researchProduct

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

2010

Abstract The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive …

glycoproteinMaleTime FactorsZAP-70Chronic lymphocytic leukemiavascular endothelial growth factor aBiochemistryGastroenterologyimmunoglobulin heavy chainsAdult Aged Aged; 80 and over Angiopoietin-2; analysis/blood Blood Chemical Analysis Female Humans Leukemia; Lymphocytic; Chronic; B-Cell; blood/diagnosis/mortality/therapy Male Middle Aged Neoadjuvant Therapy Prognosis Survival Analysis Time Factors Tumor Markers; Biological; bloodBlood plasma80 and overChronicTumor MarkersAged 80 and overLeukemiaHematologyHazard ratioprotein kinaseHematologyanalysis/bloodMiddle Agedchronic b-cell leukemiasPrognosisLymphocyticNeoadjuvant TherapyLeukemiaCohortFemaleAdultmedicine.medical_specialtyImmunologyangiopoietins chronic b-cell leukemias chronic lymphocytic leukemia plasma vascular endothelial growth factor a cd38 enzyme-linked immunosorbent assay glycoprotein immunoglobulin heavy chains protein kinaseNOcd38Angiopoietin-2bloodInternal medicinemedicineBiomarkers Tumorchronic lymphocytic leukemia angiopoietin-2.Humansbeta(2)-microglobulinplasmaSurvival analysisblood/diagnosis/mortality/therapyAgedbusiness.industryB-CellCell BiologyBiologicalmedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisConfidence intervalImmunologychronic lymphocytic leukemiaangiopoietin-2enzyme-linked immunosorbent assaybusinessCLL; angiopoietin-2; beta(2)-microglobulin; ZAP-70; CD38Settore MED/15 - Malattie del SangueangiopoietinsBlood Chemical AnalysisCLLCD38Blood Chemical Analysis; Angiopoietin-2; Humans; Neoadjuvant Therapy; Prognosis; Aged; Aged 80 and over; Leukemia Lymphocytic Chronic B-Cell; Adult; Middle Aged; Tumor Markers Biological; Time Factors; Female; Male; Survival Analysis
researchProduct

Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review

2022

Simple Summary Moving from the achievements of immune checkpoint inhibitors in metastatic lung cancer, the great promise of immunotherapy in resectable early-stage is to make a disease, often lethal until now for frequent post-surgery relapses, more curable. This review focuses on role of immunotherapy in early-stage non-small cell lung cancer. We summarize biological rationale, findings from clinical trials of adjuvant and neoadjuvant immune checkpoint inhibitors, questions about biomarkers and choice of endpoints, aiming to provide up-to-date information useful for clinical decision making. Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage …

immune checkpoint inhibitorsCancer Researchlung cancernon-small-cell lung carcinoma (NSCLC)OncologyadjuvantSettore MED/06 - Oncologia Medicaneoadjuvantadjuvant; immune checkpoint inhibitors; immunotherapy; lung cancer; neoadjuvant; non-small-cell lung carcinoma (NSCLC);immune checkpoint inhibitorimmunotherapy
researchProduct

How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells

2022

Vaccination, being able to prevent millions of cases of infectious diseases around the world every year, is the most effective medical intervention ever introduced. However, immunosenescence makes vaccines less effective in providing protection to older people. Although most studies explain that this is mainly due to the immunosenescence of T and B cells, the immunosenescence of innate immunity can also be a significant contributing factor. Alterations in function, number, subset, and distribution of blood neutrophils, monocytes, and natural killer and dendritic cells are detected in aging, thus potentially reducing the efficacy of vaccines in older individuals. In this paper, we focus on t…

immunosenescenceSettore MED/04 - Patologia GeneraleVaccinationOrganic ChemistryagingGeneral MedicinevaccinesImmunity InnateCatalysisComputer Science ApplicationsInorganic Chemistrytrained immunityAdjuvants ImmunologicadjuvantsHumansimmunostimulationdendritic cellsPhysical and Theoretical ChemistryMolecular Biologyinnate immunitySpectroscopyAged
researchProduct

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study

2017

IF 7.719; International audience; Introduction: Some studies have suggested that baseline tumor-infiltrating-lymphocytes (TILs), such as CD8+ and FoxP3+ T-cells, may be associated with a better prognosis in colorectal cancer. We sought to investigate modulation of the immune response by preoperative radiotherapy (preopRT) and its impact on survival in locally advanced rectal cancer (LARC). Materials & Methods: We analyzed data for 237 patients with LARC who received RT. Density of TILS (CD8+ and FoxP3+) in intraepithelial (iTILs) and stromal compartments (sTILs) were evaluated from surgery pathological specimens and biopsies performed at baseline. The primary endpoint was to assess the impa…

lcsh:Immunologic diseases. Allergy0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenalcsh:RC254-282radiation therapy[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointImmunology and Allergyrectal cancertranslational studyOriginal ResearchUnivariate analysisbusiness.industryTumor-infiltrating lymphocytesDose fractionationFOXP3hemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease3. Good healthRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesistumor-infiltrating lymphocyteslcsh:RC581-607businessAdjuvant
researchProduct

Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery

2020

Transcutaneous immunization (TCI) via needle-free and non-invasive drug delivery systems is a promising approach for overcoming the current limitations of conventional parenteral vaccination methods. The targeted access to professional antigen-presenting cell (APC) populations within the skin, such as Langerhans cells (LCs), various dermal dendritic cells (dDCs), macrophages, and others makes the skin an ideal vaccination site to specifically shape immune responses as required. The stratum corneum (SC) of the skin is the main penetration barrier that needs to be overcome by the vaccine components in a coordinated way to achieve optimal access to dermal APC populations that induce priming of…

lcsh:Immunologic diseases. AllergyOvalbuminMini ReviewT-Lymphocytesparticulate systemsImmunologyAntigen-Presenting CellsAdministration CutaneousSonicationDrug Delivery SystemsImmune systemtranscutaneous immunizationAdjuvants ImmunologicAntigenvaccine particlesStratum corneumHumansImmunology and AllergyMedicineVaccines Virus-Like ParticleParticle SizeTransdermalIontophoresisintegumentary systembusiness.industryElectroporationVaccinationDermisPeptide Fragmentsneedle-free vaccinationVaccinationElectroporationmedicine.anatomical_structureLangerhans CellsLiposomesImmunologyDrug deliverydrug deliveryInjections JetnanoparticlesLymph NodesPharmaceutical Vehiclesbusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

¿Es necesaria la quimio-radioterapia preoperatoria en todos los pacientes con cáncer del recto localmente avanzado? Análisis de una serie consecutiva…

2013

Antecedentes: actualmente la quimio-radioterapia preoperatoria es el método estándar de tratamiento de los pacientes con cáncer del recto localmente avanzado. Sin embargo, a partir de la estandarización de la técnica de la escisión total del mesorrecto, las recidivas locales se han reducido significativamente y algunos pacientes podrían evitar el sobretratamiento con quimio-radioterapia preoperatoria y su potencial efecto tóxico. El presente estudio ha sido diseñado con el objetivo de evaluar los factores predictivos de recidiva en una serie institucional de pacientes con cáncer rectal estadificado preoperatoriamente con ecografía rectal y/o resonancia magnética como cT2N+ o cT3 y tratados …

margen de resección crcunferencialestadificación preoperatoriaUNESCO::CIENCIAS MÉDICAS:CIENCIAS MÉDICAS::Cirugía::Cirugía abdominal [UNESCO]escisión total del mesorrectoUNESCO::CIENCIAS MÉDICAS::Cirugía::Cirugía abdominal:CIENCIAS MÉDICAS [UNESCO]cáncer rectaltratamiento neoadjuvante
researchProduct

Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.

2013

The T-helper epitope peptide P30 (green in the scheme) from tetanus toxoid was used as the immunostimulant in MUC1 glycopeptide antitumor vaccines and apparently also acts as a built-in adjuvant. P30-conjugated glycopeptide vaccines containing three glycans in the immunodominant motifs PDTRP and GSTAP induced much stronger immune responses and complement dependent cytotoxicity mediated killing of tumor cells when applied in plain PBS solution without complete Freund's adjuvant.

medicine.drug_classmedicine.medical_treatmentEpitopes T-Lymphocytecomplex mixturesImmunostimulantCancer VaccinesCatalysisEpitopeEpitopesImmune systemmedicineTetanus ToxoidHumansTetanusChemistryMucin-1ToxoidGlycopeptidesGeneral Chemistrymedicine.diseaseVirologyComplement-dependent cytotoxicityGlycopeptideEpitopes B-LymphocytePeptidesAdjuvantAngewandte Chemie (International ed. in English)
researchProduct

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program o…

2013

BACKGROUND Compliance and persistence are often overlooked in adjuvant breast cancer treatment. PATIENTS AND METHODS PACT was a prospective, multicenter, randomized, open, parallel-group study assessing whether educational materials (EMs) enhanced compliance with aromatase inhibitor (AI) therapy in postmenopausal women with early, hormone-receptor-positive (HR+) breast cancer. The primary end points were compliance (proportion taking ≥ 80% anastrozole) at 12 months and persistence (proportion reporting anastrozole intake during the study period). RESULTS Four thousand eight hundred and forty-four patients were randomly assigned 1:1 to receive standard therapy or standard therapy with EMs. T…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classmedicine.medical_treatmentAnastrozoleBreast NeoplasmsAnastrozolePactPersistence (computer science)Medication AdherenceEosinophilia–myalgia syndromeBreast cancerInternal medicineNitrilesmedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyAromatase inhibitorbusiness.industrySurrogate endpointHematologyMiddle AgedTriazolesmedicine.diseasePostmenopauseOncologyPatient ComplianceFemalebusinessAdjuvantmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct